Aurinia Pharmaceuticals Inc. (AUPH) |
| 11.32 -0.3 (-2.58%) 10-10 12:16 |
| Open: | 11.64 |
| High: | 11.64 |
| Low: | 11.295 |
| Volume: | 403,914 |
| Market Cap: | 1,490(M) |
| PE Ratio: | 26.33 |
| Exchange: | NASDAQ Global Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 13.54 |
| Resistance 1: | 12.32 |
| Pivot price: | 11.91 |
| Support 1: | 10.34 |
| Support 2: | 8.60 |
| 52w High: | 13.54 |
| 52w Low: | 6.55 |
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Financials
| EPS | 0.430 |
| Book Value | 66.700 |
| PEG Ratio | 0.00 |
| Gross Profit | 165484128.000 |
| Profit Margin (%) | 23.31 |
| Operating Margin (%) | 28.85 |
| Return on Assets (ttm) | 7.7 |
| Return on Equity (ttm) | 17.3 |
Company news
Fri, 03 Oct 2025
Could Regulatory Scrutiny Shift the Risk Profile for Aurinia Pharmaceuticals (AUPH)? - simplywall.st
Fri, 03 Oct 2025
Could Regulatory Scrutiny Shift the Risk Profile for Aurinia Pharmaceuticals (AUPH)? - Sahm
Tue, 30 Sep 2025
Aurinia responds after top FDA official’s comment on lead drug - Seeking Alpha
Mon, 29 Sep 2025
Aurinia Responds to Now Retracted LinkedIn Post - Business Wire
Wed, 06 Aug 2025
Aurinia Pharma: The Easiest Money May Have Been Made (Rating Downgrade) (NASDAQ:AUPH) - Seeking Alpha
Sun, 03 Aug 2025
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Just Beat EPS By 9.1%: Here's What Analysts Are Forecasting For This Year - Yahoo Finance
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
